Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SODA study of sofosbuvir + daclatasvir with or without ribavirin in chronic hepatitis C
NL-OMON27532Recruiting
- Sponsor
- AMC Health
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sofosbuvir, daclatasvir and ribavirin in hepatitis C virus infection (3 arms), sponsored by AMC Health. Primary endpoint: Immune response. Started Oct 2014; status: recruiting.
02
Drugs
sofosbuvirdaclatasvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON27532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27532.